Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

Clinical trial NCT07652242 · RECRUITING

Trial details

NCT number: NCT07652242
Sponsor: Immunomic Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Breast Cancer (TNBC)

Start date: 2026-06-01
Primary completion: 2028-02-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.